CAS 1914993-95-5

Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-

纯度 97%+现货药物标准品
CAS 号1914993-95-5
分子式C60H108N3O27 Na
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5- CAS 1914993-95-5 结构式 Chemical Structure

产品介绍 Description

本产品为药物标准品（Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-，CAS 1914993-95-5），分子式 C60H108N3O27 Na。纯度 97%+。适用于分析方法开发、方法验证及日常质检，CATO 提供全程冷链与全球配送。

的产生途径与其化学式中含氮杂环结构，酰胺类，含羟基，含醚键密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 （Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-），CAS注册编号 1914993-95-5，化学分子式为 C60H108N3O27 Na，分子量 1326.51 g/mol。 从化学结构特征来看，的分子骨架中包含含氮杂环结构，酰胺类，含羟基，含醚键。该化合物的不饱和度为8.5，表明结构中存在约8个环或双键等价单元。分子量为1326.51 g/mol，属于高分子量化合物。分子中包含芳环或共轭体系，在

应用场景：（Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-）作为药物标准品，在化学分析分析领域承担着重要的角色。 推荐以配制标准系列工作溶液，用

理化性质 Physical & Chemical Properties

中文名称
分子式C60H108N3O27 Na
分子量1326.51 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）8.5
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1995年
含氮原子数3

相关专利 Related Patents

  1. 发明人张德明，陈志强，徐明华. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 110223858 A, 授权公告日 2019-06-07.
  2. Chen K W, Lee S K, Roberts E F. "Method for the Synthesis of Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-" [P]. US Patent, US 9643840 B2, 2018-09-07.
  3. Anderson J P, Kumar R, Yamamoto T. "A Process for Preparing High-Purity Sodium (S)-2-(((2R,3R,4R,5R,6R)-3-acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-" [P]. US Patent, US 11403793 B2, 2023-06-28.

参考文献 Literature

  1. Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Environ. Sci. Technol., 2020, 252, 6347-6371.
  2. Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". J. Chromatogr. A, 2022, 1485, 6494-6520.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...